Fig. 8

Combination of crizotinib with IN10018 led to an enrichment of ROS, p53, and the GSH metabolic pathway. A The heatmap of MDA-MB-231cells treated with IN10018 and ROS1 inhibitors by RNA-seq. B Histograms of the number of up-regulated (red bars) and down-regulated (blue bars) genes in different groups of MDA-MB-231 cells. C Venn diagram displaying the overlaps among different groups of MDA-MB-231 cells. D Genomic enrichment analysis (GSEA) identified significant changes in the combined group of MDA-MB-231 cells compared to the control group. E KEGG analysis results were shown by a bubble diagram of MDA-MB-231 cells. F GO analysis results were shown by a bar diagram of MDA-MB-231 cells. G KEGG analysis results were shown by a bubble diagram of MDA-MB-231 tumors. H GO analysis results were shown by a bar diagram of MDA-MB-231 cells. Significant levels: ns = not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001